Regulus Therapeutics
RGLS
#6949
Rank
A$0.85 B
Marketcap
A$12.28
Share price
0.00%
Change (1 day)
421.29%
Change (1 year)

Regulus Therapeutics (RGLS) - Total debt

Total debt on the balance sheet as of March 2025 : A$2.1 Million

According to Regulus Therapeutics's latest financial reports the company's total debt is A$2.1 Million. A companyโ€™s total debt is the sum of all current and non-current debts.

Regulus Therapeutics - Total debt on balance sheet (from 2011 to 2025)

Total debt by year

Year Total debt Change
2024-12-31A$0.44 M-87.44%
2023-12-31A$3.5 M-62%
2022-12-31A$9.22 M-5.65%
2021-12-31A$9.77 M61.65%
2020-12-31A$6.04 M-71.05%
2019-12-31A$20.89 M-11.18%
2018-12-31A$23.52 M-7.51%
2017-12-31A$25.43 M-7.4%
2016-12-31A$27.47 M
2014-12-31A$28.58 M126.09%
2013-12-31A$12.64 M29.67%
2012-12-31A$9.75 M-0.01%
2011-12-31A$9.75 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
GlaxoSmithKline
GSK
A$35.92 B 1,703,111.99%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
A$38.43 B 1,822,262.60%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
A$9.92 B 470,285.44%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$49.12 B 2,329,093.43%๐Ÿ‡ฌ๐Ÿ‡ง UK
Alnylam Pharmaceuticals
ALNY
A$1.96 B 93,294.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
A$38.27 M 1,714.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$76.84 B 3,643,083.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA